_6e98296023b34dfabc133638c1ef5d32-620x480.jpg "Advances in organoids could transform the treatment of spinal cord and peripheral nerve injuries")
Boston, August 19, 2025 / PRNEWSWIRE / – Intrinsic Therapeutics, Inc., a medical technology company committed to redefining the care standard for lumbar disccetomy patients with large annular defects by reducing reopenings for rehniations by 81%* with its barricaid closure device, the appointment of the veterans of the industry in Mike Lytle announced today and the Davas of the advantages, and those of the advantages, the Viceid Decker, the president of the sales and the delights of the advantages, and the vessels of the sales and the delights of the advantages, and the vessels of the sales and those of the advantages, and the delights of the advantages and the ones of the advantages, the viceid. Vice President of Sales, this, respectively. Together, Mike and Dave contribute more than 60 years of combined experience in spine and orthopedics, along with decades of reliable relations with surgeons and distributors throughout the community of the spine.
Keith Valentine, President and CEO of Intrinsic, said: “Mike and Dave are proven leaders and builders of successful equipment, each with a history of promoting sales growth in multiple companies of high -performance spine implants. Two dacades, I know his professionalism, his professionalism, the integrity and the ability of the capacity of the matter.
Dave Decker brings more than 30 years of experience in spine and orthopedics. More recently, he served as AVP for Seaspine/Orthofix, where his area was classified as a high performance region for three consecutive years. Previously, he spent 11 years as a sales director of the area in Nuvasive, where he was repeatedly recognized as a leader of the upper area. “Barricaid represents an important advance in the treatment of disc hernia, which allows us to meet the needs of patients as never before,” said Decker. “By redefining the standard of care, we can transform the lives of innumerable patients affected by this condition.”
Mike Lytle has more than 30 years of experience in medical devices, including 17 years in the spine. He spent more than a decade like AVP in Orthofix/Seaspine, leading one of the most producing regions of the company five times. Before that, he served six years as a senior sales director at Nuvasive, winning multiple Presidman’s Club awards. When reflecting on his new role, Lytle shared: “Having personally experienced complications of a failed multilevel disccetomy, I deeply passionate about Intrinsic’s mission. Together with our surgeon partners, we have the obligation to ensure that each qualified patient has access to Barricaid so that they can avoid the challenges I faced and live healthy lives.”
About Barricaid
Barricaid is a patented technology designed to prevent reusing and reopening in patients with large annular defects after lumbar discectomy surgery. Barricaid has been implemented in more than 12,000 patients and is supported by clinical studies in eight populations of different patients, including two random controlled tests and six studies of a single arm. Jama was published in Jama, a Multican, ECA level I that demonstrates results higher than the disccetomy only with five -year follow -up results.
*Some studies are outside the FDA indications. Values in a minimum of 1 year post-Op. Minimum study size: 20 barrel subjects.
Barricaid is a registered brand of Intrinsic Therapeutics, Inc.
Intrinsic Therapeutics source, Inc.
